|
|||||
|
|
Doxorubicin chemotherapy for presumptive cardiac hemangiosarcoma in dogs† |
|
| Authors: | C.M. Mullin M.A. Arkans C.D. Sammarco D.M. Vail B.M. Britton K.R. Vickery R.E. Risbon J. Lachowicz K.E. Burgess C.A. Manley C.A. Clifford |
| Affiliation: | 1. The Oncology Service, Washington, DC, USA;2. Red Bank Veterinary Hospital, Tinton Falls, NJ, USA;3. North Carolina State University, Raleigh, NC, USA;4. University of Wisconsin School of Veterinary Medicine, Madison, WI, USA;5. BluePearl Veterinary Partners, New York, NY, USA;6. Hope Veterinary Specialists, Malvern, PA, USA;7. Veterinary Specialty & Emergency Center, Levittown, PA, USA;8. Tufts Cummings School of Veterinary Medicine, North Grafton, MA, USA |
| Abstract: | Sixty‐four dogs were treated with single‐agent doxorubicin (DOX) for presumptive cardiac hemangiosarcoma (cHSA). The objective response rate (CR + PR) was 41%, and the biologic response rate (CR + PR + SD), or clinical benefit, was 68%. The median progression‐free survival (PFS) for treated dogs was 66 days. The median survival time (MST) for this group was 116 days and was significantly improved compared to a MST of 12 days for untreated control dogs (P = 0.0001). Biologic response was significantly associated with improved PFS (P < 0.0001) and OS (P < 0.0001). Univariate analysis identified larger tumour size as a variable negatively associated with PFS. The high rate of clinical benefit and improved MST suggest that DOX has activity in canine cHSA. |
| Keywords: | chemotherapy metastasis oncology small animal surgical oncology tumour biology |